Epoetin Alfa-BioSimilar

DRUG2 trials

Sponsors

Hospital de Clinicas de Porto Alegre, Julia Xu

Conditions

Anemia, Sickle CellComparison of the Efficacy of Two Formulations of Epoetin in Patients Undergoing HemodialysisSickle Cell Disease

Phase 1

Hydroxyurea and EPO in Sickle Cell Disease

CompletedNCT05451940

Julia XuAnemia, Sickle Cell, Sickle Cell Disease

Start: 2023-05-25End: 2025-02-27Updated: 2026-01-07

Phase 3

Efficacy Study of Two Formulations of Erythropoietin

CompletedNCT01184495

Hospital de Clinicas de Porto AlegreComparison of the Efficacy of Two Formulations of Epoetin in Patients Undergoing Hemodialysis

Start: 2008-04-30End: 2009-01-31Updated: 2017-02-27

Related Papers

Raising hemoglobin level with erythropoietin improves cerebral but not muscle tissue oxygenation in patients with sickle cell disease

Blood2025-11-03

EPO treatment in combination with hydroxyurea improves pain and other quality of life measures in sickle cell disease

Blood2025-11-03

A Phase 1b/2 Study of the Efficacy and Safety of Combination Hydroxyurea and Dose-Escalated Erythropoietin for Treatment of Anemia in Sickle Cell Disease (ACHiEvE-SCD)

Blood2024-11-05

Addressing Chronic Anemia in Sickle Cell Disease: Characterizing Erythropoiesis-Stimulating Agent (ESA) Utilization and Practice Patterns Among Providers

Blood2023-11-021 citations

Randomized double-blind clinical trial of a new human epoetin versus a commercially available formula for anemia control in patients on hemodialysis.

2014-08-012 citations